Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors

Archives of Dermatology

Volumn 140, Issue 12, 2004, Pages 1490-1495

  Gilliet, Michel ^a   Conrad, Curdin ^a   Geiges, Michael ^a   Cozzio, Antonio ^a   Thürlimann, Wolfgang ^b   Burg, Günter ^a   Nestle, Frank O ^a   Dummer, Reinhard ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b Zurich University Hospital ^*

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; BDCA2 ANTIGEN; CALCIPOTRIOL; CD123 ANTIGEN; IMIQUIMOD; INTERFERON; MXA ANTIGEN; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 7 AGONIST; UNCLASSIFIED DRUG;

ADULT; ANTIGEN EXPRESSION; ARTICLE; ATOPIC DERMATITIS; AUTOIMMUNITY; BOWENOID PAPULOSIS; CASE REPORT; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE EXACERBATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; PLASMA CELL; PLASMACYTOID DENDRITIC CELL PRECURSOR; PRIORITY JOURNAL; PSORIASIS; PSORIASIS PLAQUE; SKIN BIOPSY; SKIN CELL; SKIN DEFECT; STEM CELL; T LYMPHOCYTE;

ADMINISTRATION, TOPICAL; AMINOQUINOLINES; BIOPSY; DENDRITIC CELLS; DIAGNOSTIC ERRORS; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON INDUCERS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PLASMA CELLS; PSORIASIS; RECEPTORS, CELL SURFACE; SKIN; STEM CELLS; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTORS;

EID: 10344256237     PISSN: 0003987X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archderm.140.12.1490     Document Type: Article

References (47)

1. Medzhitov R, Janeway C Jr. Innate immune recognition: mechanisms and pathways. Immunol Rev. 2000;173:89-97.
2. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol. 2001;2:675-680.
3. Zhang D, Zhang G, Hayden MS, et al. A toll-like receptor that prevents infection by uropathogenic bacteria. Science. 2004;303:1522-1526.
4. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis ESC. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science. 2004;303:1529-1531.
5. Heil F, Hemmi H, Hochrein H, et al. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science. 2004;303:1526-1529.
6. Hemmi H, Kaisho T, Takeuchi O, et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol. 2002;3:196-200.
7. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999;21:1-14.
8. Skinner RB Jr. Treatment of molluscum contagiosum with imiquimod 5% cream. J Am Acad Dermatol. 2002;47(4 suppl):S221-S224.
9. Petrow W, Gerdsen R, Uerlich M, Richter O, Bieber T. Successful topical immunotherapy of bowenoid papulosis with imiquimod. Br J Dermatol. 2001;145:1022-1023.
10. Bianchi L, Campione E, Marulli GC, Costanzo A, Chimenti S. Actinic keratosis treated with an immune response modifier: a case report of six patients. Clin Exp Dermatol. 2003;28(suppl 1):39-41.
11. Naylor MF, Crowson N, Kuwahara R, et al. Treatment of lentigo maligna with topical imiquimod. Br J Dermatol. 2003;149(suppl 66):66-70.
12. Dummer R, Urosevic M, Kempf W, Hoek K, Hafner J, Burg G. Imiquimod in basal cell carcinoma: how does it work? Br J Dermatol. 2003;149(suppl 66):57-58.
13. Schon M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst. 2003;95:1138-1149.
14. Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol. 2003;139:1325-1332.
15. Reiter MJ, Testerman TL, Miller RL, Weeks CE, Tomai MA. Cytokine induction in mice by the immunomodulator imiquimod. J Leukoc Biol. 1994;55:234-240.
16. Weeks CE, Gibson SJ. Induction of interferon and other cytokines by imiquimod and its hydroxylated metabolite R-842 in human blood cells in vitro. J Interferon Res. 1994;14:81-85.
17. Luft T, Pang KC, Thomas E, et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol. 1998;161:1947-1953.
18. Gibson SJ, Lindh JM, Riter TR, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol. 2002;218:74-86.
19. Ito T, Amakawa R, Kaisho T, et al. Interferon-alpha and interleukin-12 are induced differentially by Toll-like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med. 2002;195:1507-1512.
20. Kadowaki N, Ho S, Antonenko S, et al. Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens. J Exp Med. 2001;194:863-869.
21. Jarrossay D, Napolitani G, Colonna M, Sallusto F, Lanzavecchia A. Specialization and complementarity in microbial molecule recognition by human myeloid and plasmacytoid dendritic cells. Eur J Immunol. 2001;31:3388-3393.
22. Siegal FP, Kadowaki N, Shodell M, et al. The nature of the principal type 1 interferon-producing cells in human blood. Science. 1999;284:1835-1837.
23. Cella M, Jarrossay D, Facchetti F, et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med. 1999;5:919-923.
24. Kadowaki N, Antonenko S, Lau JY, Liu YJ. Natural interferon alpha/beta-producing cells link innate and adaptive immunity. J Exp Med. 2000;192:219-226.
25. Fonteneau JF, Gilliet M, Larsson M, et al. Activation of influenza virus-specific CD4+ and CD8+ T cells: a new role for plasmacytoid dendritic cells in adaptive immunity. Blood. 2003;101:3520-3526.
26. Seya T, Akazawa T, Uehori J, Matsumoto M, Azuma I, Toyoshima K. Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res. 2003;23:4369-4376.
27. Eriksson U, Ricci R, Hunziker L, et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nat Med. 2003;9:1484-1490.
28. Fraki JE, Briggaman RA, Lazarus GS. Transplantation of psoriatic skin onto nude mice. J Invest Dermatol. 1983;80(suppl):31s-35s.
29. Fah J, Pavlovic J, Burg G. Expression of MxA protein in inflammatory dermatoses. J Histochem Cytochem. 1995;43:47-52.
30. Dzionek A, Sohma Y, Nagafune J, et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon alpha/beta induction. J Exp Med. 2001;194:1823-1834.
31. Grouard G, Rissoan MC, Filgueira L, Durand I, Banchereau J, Liu YJ. The enigmatic plasmacytoid T cells develop into dendritic cells with interleukin (IL)-3 and CD40-ligand. J Exp Med. 1997;185:1101-1111.
32. Griffiths CE. The immunological basis of psoriasis. J Eur Acad Dermatol Venereol. 2003;17(suppl 2):1-5.
33. Kadunce DP, Krueger GG. Pathogenesis of psoriasis. Dermatol Clin. 1995;13:723-737.
34. Curry JL, Qin JZ, Bonish B, et al. Innate immune-related receptors in normal and psoriatic skin. Arch Pathol Lab Med. 2003;127:178-186.
35. Nickoloff BJ. Skin innate immune system in psoriasis: friend or foe? J Clin Invest. 1999;104:1161-1164.
36. Rosenberg EW, Noah PW, Skinner RB Jr. Psoriasis is a visible manifestation of the skin's defense against micro-organisms. J Dermatol. 1994;21:375-381.
37. Quesada JR, Gutterman JU. Psoriasis and alpha-interferon. Lancet. 1986;1:1466-1468.
38. Funk J, Langeland T, Schrumpf E, Hanssen LE. Psoriasis induced by interferon-alpha. Br J Dermatol. 1991;125:463-465.
39. Georgetson MJ, Yarze JC, Lalos AT, Webster GF, Martin P. Exacerbation of psoriasis due to interferon-alpha treatment of chronic active hepatitis. Am J Gastroenterol. 1993;88:1756-1758.
40. Pauluzzi P, Kokelj F, Perkan V, Pozzato G, Moretti M. Psoriasis exacerbation induced by interferon-alpha: report of two cases. Acta Derm Venereol. 1993;73:395.
41. Barker JN, Mitra RS, Griffiths CE, Dixit VM, Nickoloff BJ. Keratinocytes as initiators of inflammation. Lancet. 1991;337:211-214.
42. Mempel M, Voelcker V, Kollisch G, et al. Toll-like receptor expression in human keratinocytes: nuclear factor kappaB controlled gene activation by Staphylococcus aureus is toll-like receptor 2 but not toll-like receptor 4 or platelet activating factor receptor dependent. J Invest Dermatol. 2003;121:1389-1396.
43. Bendriss-Vermare N, Barthelemy C, Durand I, et al. Human thymus contains IFN-alpha-producing CD11c(-), myeloid CD11c(+), and mature interdigitating dendritic cells. J Clin Invest. 2001;107:835-844.
44. Wollenberg A, Wagner M, Gunther S, et al. Plasmacytoid dendritic cells: a new cutaneous dendritic cell subset with distinct role in inflammatory skin diseases. J Invest Dermatol. 2002;119:1096-1102.
45. Bangert C, Friedl J, Stary G, Stingl G, Kopp T. Immunopathologic features of allergic contact dermatitis in humans: participation of plasmacytoid dendritic cells in the pathogenesis of the disease? J Invest Dermatol. 2003;121:1409-1418.
46. Miettinen M, Sareneva T, Julkunen I, Matikainen S. IFNs activate toll-like receptor gene expression in viral infections. Genes Immun. 2001;2:349-355.
47. Mohty M, Vialle-Castellano A, Nunes JA, Isnardon D, Olive D, Gaugler B. IFN-alpna skews monocyte differentiation into Toll-like receptor 7-expressing dendritic cells with potent functional activities. J Immunol. 2003;171:3385-3393.